Cholesterol embolization syndrome presents a specific management challenge when the patient also has a compelling, concurrent indication for anticoagulation. This scenario has direct clinical guidance.

Clinical Scenario

This protocol addresses cholesterol embolization syndrome (cholesterol atheroembolism) in patients who carry a concurrent mandatory indication for anticoagulation therapy — specifically atrial fibrillation, a mechanical prosthetic heart valve, or a new intravascular thrombus. Current consensus supports continuing anticoagulation in these patients despite the diagnosis of cholesterol embolization syndrome.

Treatment Approach

The approach combines continued anticoagulation with measures to suppress the inflammatory response to cholesterol crystals, alongside supportive care. The full regimen — including specific agents, sequencing, and monitoring — is detailed in the complete protocol.

Clinical Goal

The primary treatment target is improvement in renal function.

References

DOI: 10.14740/jmc1804w

Current consensus is to continue anticoagulation in patients with a concurrent indication for it (e.g., mechanical prosthetic valve, new intravascular thrombus, atrial fibrillation) [25].
Because of the potential disastrous consequences of an embolus, the patient was anticoagulated with warfarin concurrently with corticosteroids to suppress the inflammatory response to cholesterol crystals.
His renal function continued to improve and was discharged without the need for dialysis.

View source ↗

Treatment of Cholesterol Atheroembolism with Concurrent Atrial Fibrillation

References